Results 261 to 270 of about 29,420 (294)
Some of the next articles are maybe not open access.
Drugs, 2001
Caspofungin is the first in a new class of antifungal agents, the glucan synthesis inhibitors, that interfere with fungal cell wall synthesis. Caspofungin exhibited in vitro and in vivo efficacy against a wide range of fungi and yeasts including Aspergillus and Candida species.
G M, Keating, B, Jarvis
+8 more sources
Caspofungin is the first in a new class of antifungal agents, the glucan synthesis inhibitors, that interfere with fungal cell wall synthesis. Caspofungin exhibited in vitro and in vivo efficacy against a wide range of fungi and yeasts including Aspergillus and Candida species.
G M, Keating, B, Jarvis
+8 more sources
Medical Mycology, 2021
Candida auris is an emergent nosocomial multi-drug-resistant yeast that represents a global health threat. Recently, C. auris clinical isolates with caspofungin resistance were identified. Mutation in FKS1 gene was determined as a mechanism of resistance.
Bahgat Fayed, M. Jayakumar, S. Soliman
semanticscholar +1 more source
Candida auris is an emergent nosocomial multi-drug-resistant yeast that represents a global health threat. Recently, C. auris clinical isolates with caspofungin resistance were identified. Mutation in FKS1 gene was determined as a mechanism of resistance.
Bahgat Fayed, M. Jayakumar, S. Soliman
semanticscholar +1 more source
Expert Review of Anti-Infective Therapy, 2021
Introduction Candida species have been regarded as global health threats due to their ability to cause invasive infections. It is challenging to treat Candida bloodstream infections, which are associated with high mortality levels.
S. Su +6 more
semanticscholar +1 more source
Introduction Candida species have been regarded as global health threats due to their ability to cause invasive infections. It is challenging to treat Candida bloodstream infections, which are associated with high mortality levels.
S. Su +6 more
semanticscholar +1 more source
Journal of Antimicrobial Chemotherapy, 2023
Abstract Objectives Caspofungin is an echinocandin antifungal agent that inhibits synthesis of glucan required for the fungal cell wall. Resistance is mediated by mutation of Fks1 glucan synthase, among which S645P is the most common resistance-associated polymorphism.
Maxime Lefranc +4 more
openaire +2 more sources
Abstract Objectives Caspofungin is an echinocandin antifungal agent that inhibits synthesis of glucan required for the fungal cell wall. Resistance is mediated by mutation of Fks1 glucan synthase, among which S645P is the most common resistance-associated polymorphism.
Maxime Lefranc +4 more
openaire +2 more sources
Drugs of Today, 2002
Available systemically effective antifungal agents for the treatment of invasive fungal infections are few. With the increasing recognition of a need for newer antifungal drugs, caspofungin has been introduced as the first member of a new class of compounds called echinocandins.
P H, Chandrasekar, E K, Manavathu
openaire +2 more sources
Available systemically effective antifungal agents for the treatment of invasive fungal infections are few. With the increasing recognition of a need for newer antifungal drugs, caspofungin has been introduced as the first member of a new class of compounds called echinocandins.
P H, Chandrasekar, E K, Manavathu
openaire +2 more sources
The first echinocandin: caspofungin
Mycoses, 2002Summary. The antifungal agent caspofungin is the first echinocandin that has been approved in the US and in Europe for treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of conventional amphotericin B, its lipid‐based formulations, and/or itraconazole.
Karina Schmitz +2 more
openaire +3 more sources
APMIS, 2006
Disseminated candidiasis is relatively common in immunocompromised patients. The treatment protocol of these patients usually includes broad‐spectrum antibiotics and also emprical antifungals initiated due to unresponsiveness to antibiotics. In this study the efficacies of caspofungin and meropenem – separately and together – in mice with disseminated ...
Serdar Filiz +5 more
openaire +3 more sources
Disseminated candidiasis is relatively common in immunocompromised patients. The treatment protocol of these patients usually includes broad‐spectrum antibiotics and also emprical antifungals initiated due to unresponsiveness to antibiotics. In this study the efficacies of caspofungin and meropenem – separately and together – in mice with disseminated ...
Serdar Filiz +5 more
openaire +3 more sources
Caspofungin in Pediatric Patients
Pediatric Health, 2008Invasive fungal infections have emerged as one of the most significant complications in severely immunocompromised pediatric patients, such as children suffering from hematological malignancies or children undergoing hematopoietic stem cell transplantation. In addition, neonates, in particular preterm infants, are at risk for invasive mycoses. Owing to
Thomas Lehrnbecher, Andreas H. Groll
openaire +2 more sources
The pharmacology and clinical use of caspofungin
Expert Opinion on Drug Metabolism & Toxicology, 2007Caspofungin was the first echinocandin to be licensed for the treatment of invasive fungal infections. Caspofungin has in vitro and in vivo activity against Candida spp. and Aspergillus spp., which constitute the majority of medically important opportunistic fungal pathogens.
Hope, William W. +2 more
openaire +4 more sources
Caspofungin: a review of its characteristics, activity, and use in intensive care units
Expert Review of Anti-Infective Therapy, 2020Introduction Candidemia is the fourth frequent reason of healthcare-related bloodstream infections in critically ill patients. For initial management of (suspected) invasive candidiasis in critically ill patients, usage of an echinocandin, e.g ...
S. Hashemian, T. Farhadi, A. Velayati
semanticscholar +1 more source